Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 15;11(4):1005.
doi: 10.3390/jcm11041005.

An Updated Review of Cardiovascular Events in Giant Cell Arteritis

Affiliations
Review

An Updated Review of Cardiovascular Events in Giant Cell Arteritis

Hubert de Boysson et al. J Clin Med. .

Abstract

Giant cell arteritis (GCA) is a systemic vasculitis with a direct and indirect increased risk of acute and chronic vascular events, affecting large and medium vessels, and responsible for most of the morbidity and mortality of this disease. We aimed in this review to provide an updated synthesis of knowledge regarding cardiovascular events observed in GCA. By definition, GCA patients are over 50 and often over 70 years old, and subsequently also present age-related cardiovascular risk factors. In addition, the systemic and vascular inflammation as well as glucocorticoids (GC) probably contribute to an accelerated atherosclerosis and to vascular changes leading to arterial stenoses and aortic dilations and/or dissections. GCA-related ischemic complications, especially ophthalmologic events, stroke or myocardial infarcts are mostly observed within the first months after the diagnosis, being mainly linked to the vasculitic process. Conversely, aortic complications, including dilations or dissections, generally occur several months or years after the diagnosis, mainly in patients with large-vessel vasculitis. In these patients, other factors such as atherosclerosis, GC-related endothelial damage and vascular wall remodeling/healing probably contribute to the vascular events. GCA management includes the detection and treatment of these previous and newly induced cardiovascular risk factors. Hence, the use of cardiovascular treatments (e.g., aspirin, anticoagulation, statins, anti-hypertensive treatments) should be evaluated individually. Aortic structural changes require regular morphologic evaluations, especially in patients with previous aortitis. The initial or secondary addition of immunosuppressants, especially tocilizumab, an anti-IL-6 receptor antibody, is discussed in patients with GCA-related cardiovascular complications and, more consensually, to limit GC-mediated comorbidities.

Keywords: aortic dilation; aortic dissection; cardiovascular event; giant cell arteritis; large vessel vasculitis; myocardial infarction; peripheral artery disease; stroke.

PubMed Disclaimer

Conflict of interest statement

de Boysson received speaker/consulting fees from Roche-Chugai.

Similar articles

Cited by

References

    1. de Boysson H., Liozon E., Ly K.H., Dumont A., Delmas C., Aouba A. The different clinical patterns of giant cell arteritis. Clin. Exp. Rheumatol. 2019;37((Suppl. 117)):57–60. - PubMed
    1. Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 2002;347:261–271. doi: 10.1056/NEJMra011913. - DOI - PubMed
    1. Agard C., Barrier J.H., Dupas B., Ponge T., Mahr A., Fradet G., Chevalet P., Masseau A., Batard E., Pottier P., et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: A case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008;59:670–676. doi: 10.1002/art.23577. - DOI - PubMed
    1. Prieto-Gonzalez S., Depetris M., Garcia-Martinez A., Espigol-Frigole G., Tavera-Bahillo I., Corbera-Bellata M., Planas-Rigol E., Alba M.A., Hernandez-Rodriguez J., Grau J.M., et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: A prospective, case-control study. Ann. Rheum. Dis. 2014;73:1388–1392. doi: 10.1136/annrheumdis-2013-204572. - DOI - PubMed
    1. Bienvenu B., Ly K.H., Lambert M., Agard C., Andre M., Benhamou Y., Bonnotte B., de Boysson H., Espitia O., Fau G., et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA) Rev. Med. Interne. 2016;37:154–165. doi: 10.1016/j.revmed.2015.12.015. - DOI - PubMed

LinkOut - more resources